Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

Intra-Cellular Therapies, Inc. Form 4 January 06, 2015

January 06	, 2015							
FOR	M 4 UNITED	STATES SE	CURITIES A	AND EXCHANGE	COMMISSION		PPROVAL	
			Washington			Number:	3235-0287	
if no lo subject Section Form 4 Form 5 obligat may co	to 16. or Filed put ions Section 17(WNERSHIP OF nge Act of 1934, of 1935 or Sectio 940	NERSHIP OF Expires: January 31 200 Estimated average burden hours per response 0. e Act of 1934, f 1935 or Section					
(Print or Type	e Responses)							
1. Name and Mates Sha	Address of Reporting ron	Syı	mbol	I Ticker or Trading erapies, Inc. [ITCI]	5. Relationship o Issuer			
	A-CELLULAR ES, INC., 3960	(M	Date of Earliest Tr fonth/Day/Year) /02/2015	ransaction	(Check all applicable) <u>X</u> Director <u>X</u> Officer (give title <u>10%</u> Owner Other (specify below) Chairman, President & CEO			
	(Street)		If Amendment, Daed(Month/Day/Year	-	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
NEW YO	RK, NY 10032				Person	whole than one R	eporting	
(City)	(State)	(Zip)	Table I - Non-I	Derivative Securities A	cquired, Disposed o	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date any (Month/Day/Y	Code	4. Securities nAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Ro	eport on a separate line	e for each class o	of securities benef	information cont required to resp	or indirectly. spond to the collect ained in this form ond unless the for ntly valid OMB con	are not m	SEC 1474 (9-02)	
	Tab	le II - Derivativ	ve Securities Acq	uired, Disposed of, or	Beneficially Owned			

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	ionDerivative	Expiration Date	Underlying Securities

Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Disposed o	Acquired (A) or Disposed of (D) (Instr. 3, 4, and		(Month/Day/Year) (Instr. 3 and 4)		4)
				Code V	/ (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 17.57	01/02/2015		А	228,380		<u>(1)</u>	01/02/2025	Common Stock	228,380

Reporting Owners

Reporting Owner Name / Address	Relationships						
r u	Director	10% Owner	Officer	Other			
Mates Sharon C/O INTRA-CELLULAR THERAPIES, INC. 3960 BROADWAY NEW YORK, NY 10032	Х		Chairman, President & CEO				
Signatures							
/s/ Lawrence J. Hineline, Attorney-in-fact 0)1/06/2015	5					
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests as to one third of the shares on January 2, 2016, one third of the shares on January 2, 2017 and one third of the shares on January 2, 2018.

Remarks:

Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.